The Effect of Chemotherapy and Radiation Therapy on Pain Levels In Head and Neck Cancer Patients

Jacari Tate, Vivian Salama MD MS, Amy Moreno, MD, Clifton Dave Fuller, MD PhD Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center², Houston, TX

Background

- Head and Neck Cancer
 - 8th most popular cancer in the United States
 - Types focused on :
 - Oral Cancer
 - Oropharyngeal cancer
 - Head and Neck Cancer usually managed with a multimodality treatment method^[2]
- Acute Pain induced by Radiation Treatment^[1]
 - Acute Mucositis
 - Oral Candidiasis
 - Xerostomia
- Patients who have undergone chemotherapy and radiotherapy will experience higher pain profiles through their radiation treatments.

Methods

- Used to collect data on each patients pain severity, treatment data (Dose, Fx/Dose, and duration), clinical features (type of cancer: oropharyngeal or oral, ECOG performance, and Karfonsky Performance Status), pain assessment (intensity, score, location and orientation), and if the patient was having concurrent chemotherapy
- Took the collected data and used it to run an individual sample T-test to determine if concurrent chemotherapy is associated with higher pain scores compared to RT alone.

Methods (continued)

Variables/ Measures


- Independent Variable
 - Concurrent Chemotherapy (recorded in the survey as a bivariant)
- Pain Score Scale
 - Recorded on a scale from 0 -10 (0 = no pain, 10 = extreme pain)

Results

• The independent sample t-test determined that the p-value for these two factors <.001 which is way below .05. (df = 138)

Figure 1. Average weekly pain scores

Average weekly pain scores



Conclusion

- radiotherapy.

Future Directions:

References

[1] Rosenthal, David I., et al. "Measuring Head and Neck CANCER Symptom Burden: The Development and Validation of the M. D. Anderson Symptom Inventory, Head and Neck Module." Wiley Online Library, John Wiley & amp; Sons, Ltd, 14 Mar. 2007, onlinelibrary.wiley.com/doi/full/10.1002/hed.20602. .

patient. OUP Academic.

Acknowledgements

This presentation is supported by the National Cancer Institute through the U54 CA096297/CA096300: UPR/MDACC Partnership for Excellence in Cancer Research Training Program.

For further information, please contact Jacari Tate at <u>itate13@pvamu.edu</u>

Table 1. Demographics of Patient Cohorts

Results (continued)

8		
Demographics	Number	Percentage
Gender		
Female	62	27.07%
Male	167	72.93%
Age		
30-50	24	10.48%
51-70	154	67.25%
71-90	51	22.27%
Race		
Caucasian	197	86.03%
Black	5	2.18%
Asian	8	3.49%
American Indian	1	.44%
Other	16	6.99%
N/A	2	.87%
Cancer Type		
Oral Cancer	100	43.67%
Oropharyngeal Cancer	129	56.33%
Concurrent Chemotherapy		
Yes	144	62.88%
No	85	37.12%

Total Average

THE UNIVERSITY OF TEXAS **MD**Anderson **Cancer** Center

• Overall, the results show that having concurrent chemotherapy or targeted therapy during radiotherapy does not cause a patient to have a higher level of pain throughout their

• Concurrent Chemotherapy or targeted therapy with radiotherapy do not have a statically significant affect on a patients pain. • A limitation of the study was some of the patients did not always take a pain survey during their weekly see visits, which resulted in having no data of their pain at certain points.

• Data for this study was collected from mostly one source, so as more data is collected and tested it my cause the results to change

[2] Epstein, J. B., & amp; Miaskowski, C. (2019, August 19). Oral pain in the cancer

https://academic.oup.com/jncimono/article/2019/53/lgz003/5551353?login=true.